We are live on ! Find out more
RAPT

RAPT Therapeutics

Delisted

RAPT was delisted on the 2nd of March, 2026.

95 hedge funds and large institutions have $626M invested in RAPT Therapeutics in 2022 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 42 increasing their positions, 15 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

90,075% more call options, than puts

Call options by funds: $14.4M | Put options by funds: $16K

180% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 15

12% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 17

0.83% less ownership

Funds ownership: 12.63%11.8% (-0.83%)

3% less funds holding

Funds holding: 9895 (-3)

9% less capital invested

Capital invested by funds: $691M → $626M (-$64.7M)

33% less funds holding in top 10

Funds holding in top 10: 96 (-3)

Holders
95
Holders Change
-3
Holders Change %
-3.06%
% of All Funds
1.53%
Holding in Top 10
6
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-33.33%
% of All Funds
0.1%
New
19
Increased
42
Reduced
15
Closed
17
Calls
$14.4M
Puts
$16K
Net Calls
+$14.4M
Net Calls Change
-$5.49M
Name Holding Trade Value Shares
Change
Change in
Stake
T. Rowe Price Associates
1
T. Rowe Price Associates
Maryland
$66.6M +$5.7M +35,643 +9%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$58.5M -$12.5M -78,051 -17%
CG
3
Column Group
California
$53.1M +$3.36K +21 +0%
State Street
4
State Street
Massachusetts
$38.4M +$13.3M +83,354 +52%
BlackRock
5
BlackRock
New York
$37.7M -$3.18M -19,891 -8%
PA
6
Perceptive Advisors
New York
$35.6M +$1.72M +10,727 +5%
Vanguard Group
7
Vanguard Group
Pennsylvania
$29.8M +$4.47M +27,908 +17%
GPP
8
Great Point Partners
Connecticut
$28.4M +$22.4M +140,196 +356%
DTC
9
Deep Track Capital
Connecticut
$25.8M +$26.1M +163,118 New
O
10
OrbiMed
New York
$24.8M
T. Rowe Price Investment Management
11
T. Rowe Price Investment Management
Maryland
$24.7M +$61.3K +383 +0.2%
B
12
Braidwell
Connecticut
$19.8M +$20M +125,000 New
KCM
13
Kingdon Capital Management
New York
$17.4M +$4.09M +25,548 +30%
RG
14
Redmile Group
California
$15.5M
Morgan Stanley
15
Morgan Stanley
New York
$15M -$282K -1,761 -2%
AI
16
Alphabet Inc
California
$10.7M
Geode Capital Management
17
Geode Capital Management
Massachusetts
$9.01M +$595K +3,720 +7%
EC
18
Euclidean Capital
New York
$8.57M
N
19
Nuveen
North Carolina
$6.55M +$733K +4,580 +12%
CS
20
Candriam SCA
Luxembourg
$6.2M
Deutsche Bank
21
Deutsche Bank
Germany
$5.67M +$3.36K +21 +0.1%
Walleye Capital
22
Walleye Capital
New York
$5.63M +$5.69M +35,552 New
SSA
23
Schonfeld Strategic Advisors
New York
$5.58M +$3.51M +21,948 +165%
WP
24
Woodline Partners
California
$5.23M -$18.9M -118,043 -78%
Norges Bank
25
Norges Bank
Norway
$5.11M +$5.17M +32,275 New

RAPT Hedge Fund Activity: Q4 2022 in Review

95 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q4 2022, worth a combined $626M — down 9.4% from $691M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new RAPT positions and 17 closed out — a net gain of 2 holders — while 42 added to existing stakes and 15 trimmed.

The largest buyer was Deep Track Capital, opening a new position worth an estimated $26.1M. The largest seller was Woodline Partners, cutting an estimated $18.9M.

  • 95 institutional investors held RAPT Therapeutics (RAPT) as of Q4 2022, down from 98 in Q3 2022.
  • Funds reported $626M of RAPT Therapeutics stock for Q4 2022, down 9.4% quarter-over-quarter.
  • 19 funds opened new RAPT Therapeutics positions in Q4 2022 and 17 closed out, a net change of +2 holders.
  • The largest RAPT Therapeutics buyer in Q4 2022 was Deep Track Capital, an estimated $26.1M added.
  • The largest RAPT Therapeutics seller in Q4 2022 was Woodline Partners, an estimated $18.9M sold.

Based on aggregated 13F filings for Q4 2022.